Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first‐line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study
Sign Up to like & getrecommendations! Published in 2021 at "Cancer"
DOI: 10.1002/cncr.33677
Abstract: The efficacy and safety of transarterial chemoembolization (TACE) plus lenvatinib in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) have not been evaluated. read more here.
Keywords: hepatocellular carcinoma; portal vein; chemoembolization plus; transarterial chemoembolization ... See more keywords
Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2022-003419
Abstract: It was with great enthusiasm that I read the recently published KEYNOTE 775. Pembrolizumab plus lenvatinib showed unprecedented results for advanced, recurrent, or metastatic endometrial cancer with improvements in overall survival, progressionfree survival, response rates,… read more here.
Keywords: endometrial cancer; plus lenvatinib; pembrolizumab plus; response ... See more keywords
Anti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Gastrointestinal Oncology"
DOI: 10.21037/jgo-22-643
Abstract: Background Lenvatinib, a multi-targeted tyrosine kinase inhibitor (TKI), has proven efficacy as the first-line treatment for patients with advanced hepatocellular carcinoma (HCC). However, there is no standard effective second-line treatment option following progression on lenvatinib… read more here.
Keywords: plus lenvatinib; patients unresectable; antibodies plus; treatment ... See more keywords
Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.945915
Abstract: Purpose We conducted a retrospective study to compare transarterial chemoembolization (TACE) plus lenvatinib plus programmed death-1 (PD-1) inhibitors with TACE plus lenvatinib in patients with unresectable hepatocellular carcinoma (HCC). Patients and methods Patients with HCC… read more here.
Keywords: plus lenvatinib; tace; patients unresectable; transarterial chemoembolization ... See more keywords
Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1115109
Abstract: Introduction Patients with intermediate or locally advanced hepatocellular carcinoma (HCC) who are not eligible for radical treatment typically have a poor overall prognosis. Treatment strategies that can convert unresectable HCC into resectable HCC may improve… read more here.
Keywords: locally advanced; plus lenvatinib; intermediate locally; hcc ... See more keywords